$ALXO

Wong Shelly sold $3K of ALXO

Wong Shelly (SVP, FINANCE AND CAO) sold 1,404 shares of ALX ONCOLOGY HOLDINGS INC (ALXO) at $2.04 on 2026-07-01.

Original reporting
SEC EDGAR · Wong Shelly
Published Jul 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALXO
Neutral
medium confidence
Mentioned
$ALXO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALXONeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not provide new operational, financial, or regulatory information about ALXO.

02

Market read

Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the filing text.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled personal liquidity needs; without additional context, the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06, transaction dated 2026-07-01

Background

The article is an SEC Form 4 insider transaction disclosure for ALX Oncology Holdings Inc.

Company-level read

Ticker impact

$ALXONeutralMedium confidence
Context

ALX Oncology disclosed an insider open-market sale by SVP Finance and CAO Wong Shelly of 1,404 shares at $2.04 on 2026-07-01.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

Form 4 provides transaction details but not new company performance, guidance, or regulatory/operational catalysts. The article does not indicate a material change in ownership beyond the small sale.

Market effects

No sector read-through is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret it as higher near-term risk, even if the sale size is modest.

Key entities

  • ALX Oncology Holdings Inc

    Subject of the Form 4 insider transaction disclosure.

  • Wong Shelly

    SVP, Finance and CAO who sold 1,404 shares in an open-market transaction.

Related articles

$ALXOMed

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.

$ALXOMed

ALX ONCOLOGY HOLDINGS INC (ALXO): Results of Operations and Financial Condition

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in com